falsified semaglutide Hypoglycaemic coma induced by a product: a case report Call to Action: Practitioners Need

Avoid adding sugar and heavy cream

This economic pressure can also lead to tighter healthcare budgets and slower adoption of premium-priced therapies like GLP-1 drugs

The HealthRX prescribing team uses a four-factor selection framework when choosing between semaglutide and tirzepatide for a new patient: (1) insurance prior-authorization likelihood based on diagnosis codes and payer type, (2) baseline HbA1c and fasting glucose to determine whether GIP-receptor co-agonism adds glycemic benefit, (3) patient-reported history of nausea with prior GLP-1 exposure, and (4) whether the patient has a documented BMI 30 or a qualifying comorbidity at BMI 27, since that threshold governs Zepbound coverage under most commercial plans

Ozempic: the SUSTAIN trials Ozempic was studied in the SUSTAIN trial programme, primarily in people with type 2 diabetes